
## A D'alessio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5648660/publications.pdf Version: 2024-02-01



A D'ALESSIO

#	Article	IF	CITATIONS
1	Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. Leukemia, 2021, 35, 635-638.	7.2	30
2	COVID-19 and Obesity: Is Bariatric Surgery Protective? Retrospective Analysis on 2145 Patients Undergone Bariatric-Metabolic Surgery from High Volume Center in Italy (Lombardy). Obesity Surgery, 2021, 31, 942-948.	2.1	16
3	Immune and cellular damage biomarkers to predict COVID-19 mortality in hospitalized patients. Current Research in Immunology, 2021, 2, 155-162.	2.8	4
4	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. TH Open, 2021, 05, e56-e65.	1.4	9
5	Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction. TH Open, 2021, 05, e253-e263.	1.4	16
6	Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report. BMC Infectious Diseases, 2021, 21, 811.	2.9	8
7	JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. Journal of Clinical Medicine, 2021, 10, 3752.	2.4	7
8	Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World Journal of Gastroenterology, 2021, 27, 6180-6190.	3.3	4
9	On Cancer, COVID-19, and CT Scans: A Monocentric Retrospective Study. Journal of Clinical Medicine, 2020, 9, 3935.	2.4	4
10	Thrombin generation predicts early recurrence in breast cancer patients. Journal of Thrombosis and Haemostasis, 2020, 18, 2220-2231.	3.8	17
11	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. Haematologica, 2020, 105, 1704-1711.	3.5	21
12	Extensive Characterization of the Hemostatic Derangement Occurring in COVID-19 Patients Admitted to the Bergamo Hospital. Blood, 2020, 136, 36-36.	1.4	1
13	Thrombin Generation and D-Dimer Significantly Predict for Early Disease Progression and Mortality in Patients with Gastrointestinal Cancer. Blood, 2020, 136, 32-32.	1.4	0
14	A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy. Blood, 2019, 134, 2426-2426.	1.4	1
15	Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy. Blood, 2019, 134, 3642-3642.	1.4	0
16	Hemostatic biomarkers levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study. Thrombosis Research, 2018, 164, S198-S199.	1.7	0
17	Pre-Chemotherapy Levels of Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Metastatic Cancer Patients from the Hypercan Study. Blood, 2018, 132, 3795-3795.	1.4	0
18	Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. Cancer Investigation, 2017, 35, 490-499.	1.3	13

A D'ALESSIO

#	Article	IF	CITATIONS
19	Cutaneous Toxicity from Epidermal Growth Factor Receptor Inhibitors: Would a Subcutaneous Desensitization be Helpful? Case Report. Tumori, 2016, 102, S65-S68.	1.1	5
20	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thrombosis Research, 2016, 140, S55-S59.	1.7	29
21	Liver Surface Deformability: A Novel Ultrasound Technique in the Non-Invasive Assessment of Hepatic Fibrosis. Journal of Hepatology, 2016, 64, S736.	3.7	Ο
22	Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. Journal of Clinical Oncology, 2014, 32, 3607-3612.	1.6	91
23	Low Molecular Weight Heparin Modulates Thrombin Generation in Cancer Patients Undergoing Antithrombotic Therapy for Overt Venous Thromboembolism. Blood, 2014, 124, 1539-1539.	1.4	Ο
24	Catheter-based Radiofrequency Renal Sympathetic Denervation for Resistant Hypertension. Journal of Vascular and Interventional Radiology, 2013, 24, 632-639.	0.5	16
25	OC-11 Residual vein thrombosis (RVT) for assessing the optimal management of deep vein thrombosis in cancer patients: an interim analysis of the cancer DACUS study. Thrombosis Research, 2010, 125, S164.	1.7	Ο
26	The Optimal Duration of Anticoagulant Therapy In Patients with Cancer-Related Deep Vein Thrombosis: The Advantage of Using Residual Vein Thrombosis (the Cancer-DACUS Study). Blood, 2010, 116, 190-190.	1.4	5
27	Acute Promyelocytic Leukemia Toluidine Blue Subtype. Leukemia and Lymphoma, 1995, 18, 57-60.	1.3	5
28	Acute promyelocytic leukemia: morphological and clinical features. Haematologica, 1993, 78, 156-61.	3.5	8
29	Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia. Asian Journal of Medicine and Health, 0, , 15-26.	0.1	0
30	Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	6